Identifying differential predictive biomarkers for anti-interleukin-6 receptor and anti-tumor necrosis factor-α in active rheumatoid arthritis: MONARCH biomarker analyses

Introduction: The identification of predictive and pharmacodynamic biomarkers to treatment response is of utmost importance to improve clinical and economic outcomes in patients with active rheumatoid arthritis (RA) [ref:1]. Here, we identified blood-based predictive and pharmacodynamic biomarkers [for full text, please go to the a.m. URL]